Product Description
For Analgesic Allergy (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02775981)
Mechanisms of Action: DR Binder
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pharmaceutical Project Solutions
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Environmental Hypersensitivity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTS2015014 | P1 |
Completed |
Environmental Hypersensitivity |
2016-07-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|